Literature DB >> 21704549

Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics.

Eric B Fauman1, Brajesh K Rai, Enoch S Huang.   

Abstract

A target is druggable if it can be modulated in vivo by a drug-like molecule. The general properties of oral drugs are summarized by the 'rule of 5' which specifies parameters related to size and lipophilicity. Structure-based target druggability assessment consists of predicting ligand-binding sites on the protein that are complementary to these drug-like properties. Automated identification of ligand-binding sites can use geometrical considerations alone or include specific physicochemical properties of the protein surface. Features of a pocket's size and shape, together with measures of its hydrophobicity, are most informative in identifying suitable drug-binding pockets. The recent availability of several validation sets of druggable versus undruggable targets has helped fuel the development of more elaborate methods.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21704549     DOI: 10.1016/j.cbpa.2011.05.020

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  46 in total

Review 1.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

Review 2.  Genetic Approaches to Facilitate Antibacterial Drug Development.

Authors:  Dirk Schnappinger
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-13       Impact factor: 6.915

Review 3.  Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger.

Authors:  Mahdi Karimi; Parham Sahandi Zangabad; Fatemeh Mehdizadeh; Hedieh Malekzad; Alireza Ghasemi; Sajad Bahrami; Hossein Zare; Mohsen Moghoofei; Amin Hekmatmanesh; Michael R Hamblin
Journal:  Nanoscale       Date:  2017-01-26       Impact factor: 7.790

Review 4.  The PROTACtable genome.

Authors:  Melanie Schneider; Chris J Radoux; Andrew Hercules; David Ochoa; Ian Dunham; Lykourgos-Panagiotis Zalmas; Gerhard Hessler; Sven Ruf; Veerabahu Shanmugasundaram; Michael M Hann; Pam J Thomas; Markus A Queisser; Andrew B Benowitz; Kris Brown; Andrew R Leach
Journal:  Nat Rev Drug Discov       Date:  2021-07-20       Impact factor: 84.694

5.  Ultra-High-Throughput Structure-Based Virtual Screening for Small-Molecule Inhibitors of Protein-Protein Interactions.

Authors:  David K Johnson; John Karanicolas
Journal:  J Chem Inf Model       Date:  2016-01-14       Impact factor: 4.956

6.  DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites.

Authors:  Ragul Gowthaman; Sven A Miller; Steven Rogers; Jittasak Khowsathit; Lan Lan; Nan Bai; David K Johnson; Chunjing Liu; Liang Xu; Asokan Anbanandam; Jeffrey Aubé; Anuradha Roy; John Karanicolas
Journal:  J Med Chem       Date:  2015-07-10       Impact factor: 7.446

Review 7.  Bioinformatics and variability in drug response: a protein structural perspective.

Authors:  Jennifer L Lahti; Grace W Tang; Emidio Capriotti; Tianyun Liu; Russ B Altman
Journal:  J R Soc Interface       Date:  2012-05-02       Impact factor: 4.118

Review 8.  Modelling three-dimensional protein structures for applications in drug design.

Authors:  Tobias Schmidt; Andreas Bergner; Torsten Schwede
Journal:  Drug Discov Today       Date:  2013-11-08       Impact factor: 7.851

9.  Structural properties of non-traditional drug targets present new challenges for virtual screening.

Authors:  Ragul Gowthaman; Eric J Deeds; John Karanicolas
Journal:  J Chem Inf Model       Date:  2013-08-13       Impact factor: 4.956

10.  Host-rabies virus protein-protein interactions as druggable antiviral targets.

Authors:  Usha F Lingappa; Xianfu Wu; Amanda Macieik; Shao Feng Yu; Andy Atuegbu; Michael Corpuz; Jean Francis; Christine Nichols; Alfredo Calayag; Hong Shi; James A Ellison; Emma K T Harrell; Vinod Asundi; Jaisri R Lingappa; M Dharma Prasad; W Ian Lipkin; Debendranath Dey; Clarence R Hurt; Vishwanath R Lingappa; William J Hansen; Charles E Rupprecht
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.